Home > Result Summaries: Compounds > Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated P

Result Summaries: Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated P

GSK Study ID	Phase	Title	Summary (Download)
105910	phase 3	Compare immunogenicity & reactogenicity of 2 formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects (0 citation(s))
107005_	phase 3	To assess safety, reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age. (20 citation(s))
109507	phase 3	Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines (5 citation(s))
110215_	phase 3	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals’ Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16–18 months (3 citation(s))
110870_2	phase 3	Immunogenicity & safety study of a booster dose of an investigational vaccination regimen given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers (0 citation(s))
112830_	phase 3	Persistence of antibodies after full vaccination course with GSK Biologicals’ Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age (1 citation(s))
114535	n\a	Blinded retrospective laboratory evaluations to assess the serologic response to Porcine circovirus type 1 (PCV-1) in the serum of infants aged 2 and 6 months and toddlers aged 4-6 years following administration of GlaxoSmithKline (GSK) Biologicals’ IPV-containing vaccines (0 citation(s))
217744/049	phase 3	Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months (1 citation(s))
217744/054	phase 3	Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV vaccine mixed with Hib vaccine to healthy infants at 3, 5 and 11 months of age, compared to each vaccine administered separately (3 citation(s))
217744/088	phase 4	Phase IV, prospective study of the safety of GSK Bios' Pediarix administered to a cohort of infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study) (1 citation(s))